United States securities and exchange commission logo





                           September 8, 2020

       Theodore Schroeder
       Chief Executive Officer
       Nabriva Therapeutics plc
       25-28 North Wall Quay, IFSC
       Dublin 1, Ireland

                                                        Re: Nabriva
Therapeutics plc
                                                            Registration
Statement on Form S-3
                                                            Filed September 1,
2020
                                                            File No. 333-248530

       Dear Mr. Schroeder:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jeffrey
Gabor at 202-551-2544 with any questions.




                           Sincerely,


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Brian A. Johnson, Esq.